Mohamed H. Shahin
Mohamed H. Shahin has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Amanda Darekar
Pfizer R&D UK Ltd., Tadworth, UK
2 shared publications - Bimal Malhotra
Pfizer Inc., New York, USA
2 shared publications Ding Ding
Pfizer Inc. Groton Connecticut USA
2 shared publicationsOgert Fisniku
Pfizer Inc. Lake Forest Illinois USA
2 shared publications- Qi Liu
Office of Translational Sciences, Center for Drug Evaluation and Research U.S. Food and Drug Administration Silver Spring Maryland USA
2 shared publications Abhijeet Jakate
Pfizer Inc. New York New York USA
1 shared publication
Latest Publications
- Open Access
- 8 January 2026
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (5) , 1050-1057
A phase 1 study of the breast milk and plasma pharmacokinetics of zavegepant 10 mg intranasal dose in healthy lactating women
Objective: This study evaluated the pharmacokinetics of zavegepant in human breast milk and plasma following a single, 10 mg dose of zavegepant nasal spray. Background: Zavegepant nasal spray is a member of the gepant class of medications; small molecule inhibitors of the calcitonin gene‐related peptide receptor. It is approved in the United States for the acute treatment of migraine with or without aura in adults. However, the transfer of zavegepant to human breast milk in lactating women has not been assessed previously. Methods: In this Phase 1, open‐label, single‐arm, single‐dose, pharmacokinetic study (NCT06453356), 12 healthy lactating women received a single intranasal dose of 10 mg zavegepant. Blood and breast milk samples were collected over 24 h postdose to assess zavegepant pharmacokinetics. Safety was also assessed. The study was conducted from June 10 to September 26, 2024 at a single‐site in the United States. Results: Geometric mean (geometric percent coefficient of variation [CV%]) milk‐to‐plasma zavegepant concentration ratios were 0.21 (102%), 0.16 (76%), and 0.04 (130%) for area under the concentration–time curve from time 0 to 24 h postdose, area under the concentration–time curve from time 0 extrapolated to infinity, and maximum concentration, respectively. The geometric mean (geometric CV%) body weight normalized infant dose was 0.05 μg/kg/day (120%) and the geometric mean (geometric CV%) body weight normalized maternal dose was 132.8 μg/kg/day (10%). This resulted in a geometric mean (geometric CV%) relative infant dose of 0.04% (128%). One treatment‐emergent adverse event (TEAE; mild dizziness) was reported in one (8%) participant. This TEAE was considered mild in severity. No clinically meaningful abnormalities were observed for vital signs, clinical laboratory testing, and local nasal assessments. Conclusion: A single intranasal dose of 10 mg zavegepant was generally safe and well tolerated in healthy lactating women and the estimated infant exposure to zavegepant via breast milk is very low.
- 8 January 2026
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (5) , 1050-1057
Open AccessA phase 1 study of the breast milk and plasma pharmacokinetics of zavegepant 10 mg intranasal dose in healthy lactating women
Objective: This study evaluated the pharmacokinetics of zavegepant in human breast milk and plasma following a single, 10 mg dose of zavegepant nasal spray. Background: Zavegepant nasal spray is a member of the gepant class of medications; small molecule inhibitors of the calcitonin gene‐related peptide receptor. It is approved in the United States for the acute treatment of migraine with or without aura in adults. However, the transfer of zavegepant to human breast milk in lactating women has not been assessed previously. Methods: In this Phase 1, open‐label, single‐arm, single‐dose, pharmacokinetic study (NCT06453356), 12 healthy lactating women received a single intranasal dose of 10 mg zavegepant. Blood and breast milk samples were collected over 24 h postdose to assess zavegepant pharmacokinetics. Safety was also assessed. The study was conducted from June 10 to September 26, 2024 at a single‐site in the United States. Results: Geometric mean (geometric percent coefficient of variation [CV%]) milk‐to‐plasma zavegepant concentration ratios were 0.21 (102%), 0.16 (76%), and 0.04 (130%) for area under the concentration–time curve from time 0 to 24 h postdose, area under the concentration–time curve from time 0 extrapolated to infinity, and maximum concentration, respectively. The geometric mean (geometric CV%) body weight normalized infant dose was 0.05 μg/kg/day (120%) and the geometric mean (geometric CV%) body weight normalized maternal dose was 132.8 μg/kg/day (10%). This resulted in a geometric mean (geometric CV%) relative infant dose of 0.04% (128%). One treatment‐emergent adverse event (TEAE; mild dizziness) was reported in one (8%) participant. This TEAE was considered mild in severity. No clinically meaningful abnormalities were observed for vital signs, clinical laboratory testing, and local nasal assessments. Conclusion: A single intranasal dose of 10 mg zavegepant was generally safe and well tolerated in healthy lactating women and the estimated infant exposure to zavegepant via breast milk is very low.
- Open Access
- 3 November 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (11) , e70383
Artificial Intelligence in Clinical and Translational Science : From Bench Insights to Bedside Impact
- 3 November 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (11) , e70383
Open AccessArtificial Intelligence in Clinical and Translational Science : From Bench Insights to Bedside Impact
- Open Access
- 23 October 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (10) , e70348
Application of Machine Learning for Predicting Progression‐Free and Overall Survival in Patients With Renal Cell Carcinoma
Patient outcomes in advanced renal cell carcinoma (RCC) remain poor, with five‐year survival rates ranging from ~10% to 30%. Early projections of therapeutic outcomes could optimize precision medicine and accelerate drug development. While machine learning (ML) models integrating tumor growth inhibition (TGI) metrics have improved survival predictions over traditional models, their application in RCC remains unexplored. Herein, we used TGI metrics and baseline data to evaluate parametric (PM) and semi‐parametric (SPM) survival models alongside ML approaches for predicting progression‐free (PFS) and overall survival (OS) in 1839 RCC patients from four trials (evaluating sunitinib, axitinib, sorafenib, interferon‐alpha, and avelumab + axitinib). Data were split into training (70%) and testing (30%), and feature selection was used to determine parsimonious and robust models. Bootstrap resampling ( n = 100) was employed for models' validation, and performance was assessed using C‐index and Integrated Brier Score. In brief, training data results demonstrated that tree‐based ML models (random survival forest (RSF) and XGBoost) outperformed PM and SPM models in predicting PFS (C‐index: 0.783–0.785 vs. 0.725–0.738 for PM and SPM; p < 0.05) and OS (C‐index: 0.77–0.867 vs. 0.750–0.758 for PM and SPM; p < 0.05), with RSF achieving better prediction of PFS and OS using only 3–5 covariates, compared to 9–35 with other tested methods. Tree‐based methods were also superior in the testing data. SHapley Additive exPlanations revealed nonlinear relationships among top predictors, including TGI metrics, underscoring the ability of tree‐based methods to capture complex prognostic interactions. Further validation is required to confirm models' generalizability to additional therapies and patients with differing tumor severity.
- 23 October 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (10) , e70348
Open AccessApplication of Machine Learning for Predicting Progression‐Free and Overall Survival in Patients With Renal Cell Carcinoma
Patient outcomes in advanced renal cell carcinoma (RCC) remain poor, with five‐year survival rates ranging from ~10% to 30%. Early projections of therapeutic outcomes could optimize precision medicine and accelerate drug development. While machine learning (ML) models integrating tumor growth inhibition (TGI) metrics have improved survival predictions over traditional models, their application in RCC remains unexplored. Herein, we used TGI metrics and baseline data to evaluate parametric (PM) and semi‐parametric (SPM) survival models alongside ML approaches for predicting progression‐free (PFS) and overall survival (OS) in 1839 RCC patients from four trials (evaluating sunitinib, axitinib, sorafenib, interferon‐alpha, and avelumab + axitinib). Data were split into training (70%) and testing (30%), and feature selection was used to determine parsimonious and robust models. Bootstrap resampling ( n = 100) was employed for models' validation, and performance was assessed using C‐index and Integrated Brier Score. In brief, training data results demonstrated that tree‐based ML models (random survival forest (RSF) and XGBoost) outperformed PM and SPM models in predicting PFS (C‐index: 0.783–0.785 vs. 0.725–0.738 for PM and SPM; p < 0.05) and OS (C‐index: 0.77–0.867 vs. 0.750–0.758 for PM and SPM; p < 0.05), with RSF achieving better prediction of PFS and OS using only 3–5 covariates, compared to 9–35 with other tested methods. Tree‐based methods were also superior in the testing data. SHapley Additive exPlanations revealed nonlinear relationships among top predictors, including TGI metrics, underscoring the ability of tree‐based methods to capture complex prognostic interactions. Further validation is required to confirm models' generalizability to additional therapies and patients with differing tumor severity.
- Open Access
- 18 June 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (6) , e70199
A Pharmacokinetic Study of Zavegepant Nasal Spray in Healthy Adults Comparing Conventional Venous Blood Sampling With Patient‐Centric Microsampling
This Phase 1, non‐randomized, open‐label, 2‐period study compared the pharmacokinetics (PK) of zavegepant nasal spray, using samples collected via patient‐centric microsampling (PCS) devices, with those collected through venous phlebotomy (NCT05948085). Fourteen healthy participants received a single intranasal dose of 10 mg zavegepant on Days 1 and 2. Blood samples for PK analysis were collected at 0.5, 1, 2, 4, 8, and 12 h post dose on Day 1 using the Tasso‐Plus device (n = 7; produces serum samples), Tasso‐M20 (n = 7; produces dried blood samples), and venous phlebotomy (n = 14). PK parameters were calculated using non‐compartmental methods. Natural log‐transformed areas under the plasma/serum concentration‐time profile from time zero to the time of the last quantifiable concentration (AUClast) and maximum serum/plasma concentration (Cmax) of zavegepant were analyzed using a mixed‐effects model, with blood collection as a fixed effect and participant as a random effect. Of the two PCS devices assessed, the results of the Tasso‐Plus device showed successful bridging with venous phlebotomy sampling. For Tasso‐Plus versus venous phlebotomy, 39 of 41 (95.1%) data pairs met concentration correlation criteria (difference within 20% of the mean), median zavegepant concentration‐time profiles were comparable, and 90% confidence intervals for geometric mean ratios for AUClast and Cmax were wholly within the range of bioequivalence acceptance (80%–125%). The results of this study confirm that it is feasible to use serum derived from Tasso‐Plus collection of whole capillary blood as a reliable PCS approach for PK analysis of zavegepant.
- 18 June 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (6) , e70199
Open AccessA Pharmacokinetic Study of Zavegepant Nasal Spray in Healthy Adults Comparing Conventional Venous Blood Sampling With Patient‐Centric Microsampling
This Phase 1, non‐randomized, open‐label, 2‐period study compared the pharmacokinetics (PK) of zavegepant nasal spray, using samples collected via patient‐centric microsampling (PCS) devices, with those collected through venous phlebotomy (NCT05948085). Fourteen healthy participants received a single intranasal dose of 10 mg zavegepant on Days 1 and 2. Blood samples for PK analysis were collected at 0.5, 1, 2, 4, 8, and 12 h post dose on Day 1 using the Tasso‐Plus device (n = 7; produces serum samples), Tasso‐M20 (n = 7; produces dried blood samples), and venous phlebotomy (n = 14). PK parameters were calculated using non‐compartmental methods. Natural log‐transformed areas under the plasma/serum concentration‐time profile from time zero to the time of the last quantifiable concentration (AUClast) and maximum serum/plasma concentration (Cmax) of zavegepant were analyzed using a mixed‐effects model, with blood collection as a fixed effect and participant as a random effect. Of the two PCS devices assessed, the results of the Tasso‐Plus device showed successful bridging with venous phlebotomy sampling. For Tasso‐Plus versus venous phlebotomy, 39 of 41 (95.1%) data pairs met concentration correlation criteria (difference within 20% of the mean), median zavegepant concentration‐time profiles were comparable, and 90% confidence intervals for geometric mean ratios for AUClast and Cmax were wholly within the range of bioequivalence acceptance (80%–125%). The results of this study confirm that it is feasible to use serum derived from Tasso‐Plus collection of whole capillary blood as a reliable PCS approach for PK analysis of zavegepant.
- Open Access
- 11 April 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (4) , e70203
AI‐Driven Applications in Clinical Pharmacology and Translational Science: Insights From the ASCPT 2024 AI Preconference
Artificial intelligence (AI) is driving innovation in clinical pharmacology and translational science with tools to advance drug development, clinical trials, and patient care. This review summarizes the key takeaways from the AI preconference at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2024 Annual Meeting in Colorado Springs, where experts from academia, industry, and regulatory bodies discussed how AI is streamlining drug discovery, dosing strategies, outcome assessment, and patient care. The theme of the preconference was centered around how AI can empower clinical pharmacologists and translational researchers to make informed decisions and translate research findings into practice. The preconference also looked at the impact of large language models in biomedical research and how these tools are democratizing data analysis and empowering researchers. The application of explainable AI in predicting drug efficacy and safety, and the ethical considerations that should be applied when integrating AI into clinical and biomedical research were also touched upon. By sharing these diverse perspectives and real‐world examples, this review shows how AI can be used in clinical pharmacology and translational science to bring efficiency and accelerate drug discovery and development to address patients' unmet clinical needs.
- 11 April 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (4) , e70203
Open AccessAI‐Driven Applications in Clinical Pharmacology and Translational Science: Insights From the ASCPT 2024 AI Preconference
Artificial intelligence (AI) is driving innovation in clinical pharmacology and translational science with tools to advance drug development, clinical trials, and patient care. This review summarizes the key takeaways from the AI preconference at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2024 Annual Meeting in Colorado Springs, where experts from academia, industry, and regulatory bodies discussed how AI is streamlining drug discovery, dosing strategies, outcome assessment, and patient care. The theme of the preconference was centered around how AI can empower clinical pharmacologists and translational researchers to make informed decisions and translate research findings into practice. The preconference also looked at the impact of large language models in biomedical research and how these tools are democratizing data analysis and empowering researchers. The application of explainable AI in predicting drug efficacy and safety, and the ethical considerations that should be applied when integrating AI into clinical and biomedical research were also touched upon. By sharing these diverse perspectives and real‐world examples, this review shows how AI can be used in clinical pharmacology and translational science to bring efficiency and accelerate drug discovery and development to address patients' unmet clinical needs.
- Top Cited PapersOpen Access
- 8 March 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (3) , e70188
Agents for Change: Artificial Intelligent Workflows for Quantitative Clinical Pharmacology and Translational Sciences
Artificial intelligence (AI) is making a significant impact across various industries, including healthcare, where it is driving innovation and increasing efficiency. In the fields of Quantitative Clinical Pharmacology (QCP) and Translational Sciences (TS), AI offers the potential to transform traditional practices through the use of agentic workflows—systems with different levels of autonomy where specialized AI agents work together to perform complex tasks, while keeping “human in the loop.” These workflows can simplify processes, such as data collection, analysis, modeling, and simulation, leading to greater efficiency and consistency. This review explores how these AI‐powered agentic workflows can help in addressing some of the current challenges in QCP and TS by streamlining pharmacokinetic and pharmacodynamic analyses, optimizing clinical trial designs, and advancing precision medicine. By integrating domain‐specific tools while maintaining data privacy and regulatory standards, well‐designed agentic workflows empower scientists to automate routine tasks and make more informed decisions. Herein, we showcase practical examples of AI agents in existing platforms that support QCP and biomedical research and offer recommendations for overcoming potential challenges involved in implementing these innovative workflows. Looking ahead, fostering collaborative efforts, embracing open‐source initiatives, and establishing robust regulatory frameworks will be key to unlocking the full potential of agentic workflows in advancing QCP and TS. These efforts hold the promise of speeding up research outcomes and improving the efficiency of drug development and patient care.
- 8 March 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (3) , e70188
Top Cited PapersOpen AccessAgents for Change: Artificial Intelligent Workflows for Quantitative Clinical Pharmacology and Translational Sciences
Artificial intelligence (AI) is making a significant impact across various industries, including healthcare, where it is driving innovation and increasing efficiency. In the fields of Quantitative Clinical Pharmacology (QCP) and Translational Sciences (TS), AI offers the potential to transform traditional practices through the use of agentic workflows—systems with different levels of autonomy where specialized AI agents work together to perform complex tasks, while keeping “human in the loop.” These workflows can simplify processes, such as data collection, analysis, modeling, and simulation, leading to greater efficiency and consistency. This review explores how these AI‐powered agentic workflows can help in addressing some of the current challenges in QCP and TS by streamlining pharmacokinetic and pharmacodynamic analyses, optimizing clinical trial designs, and advancing precision medicine. By integrating domain‐specific tools while maintaining data privacy and regulatory standards, well‐designed agentic workflows empower scientists to automate routine tasks and make more informed decisions. Herein, we showcase practical examples of AI agents in existing platforms that support QCP and biomedical research and offer recommendations for overcoming potential challenges involved in implementing these innovative workflows. Looking ahead, fostering collaborative efforts, embracing open‐source initiatives, and establishing robust regulatory frameworks will be key to unlocking the full potential of agentic workflows in advancing QCP and TS. These efforts hold the promise of speeding up research outcomes and improving the efficiency of drug development and patient care.
- Open Access
- 9 March 2023
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 48 (3) , 257-269
Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor Overactivity
Background and Objective Fesoterodine is a muscarinic receptor antagonist approved for the treatment of overactive bladder (OAB) in adults and neurogenic detrusor overactivity (NDO) in pediatric patients. This work aimed to characterize the population pharmacokinetics of 5-hydroxymethyl tolterodine (5-HMT, the active metabolite of fesoterodine) and its pharmacokinetic/pharmacodynamic relationship in pediatric patients with OAB or NDO following administration of fesoterodine. Methods 5-HMT plasma concentrations from 142 participants of age ≥ 6 years were analyzed, and a nonlinear mixed-effects model was developed. Weight-based simulations of 5-HMT exposure and maximum cystometric capacity (MCC) were conducted using the final models. Results A one-compartment model with first-order absorption and a lag time, which included the effects of body weight, sex, cytochrome (CYP) 2D6 metabolizer status and fesoterodine formulation on pharmacokinetic parameters, best described the 5-HMT pharmacokinetics. An Emax model described the exposure–response relationship adequately. The median maximum concentration at steady state for pediatric patients weighing 25–35 kg and receiving 8 mg once daily (QD) was estimated to be 2.45 times greater than that in adults receiving 8 mg QD. Furthermore, simulation results showed dosing with fesoterodine 4 mg QD to pediatric patients weighing 25–35 kg and 8 mg QD to pediatric patients weighing >35 kg would achieve adequate exposure to demonstrate a clinically meaningful change from baseline (CFB) MCC. Conclusions Population models were developed for 5-HMT and MCC in pediatric patients. Weight-based simulations indicated that 4 mg QD for pediatric patients weighing 25–35 kg and 8 mg QD for those weighing > 35 kg provided similar exposures to those in adults following 8 mg QD and a clinically meaningful CFB MCC. Clinical Trial Numbers NCT00857896, NCT01557244
- 9 March 2023
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 48 (3) , 257-269
Open AccessPopulation Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor Overactivity
Background and Objective Fesoterodine is a muscarinic receptor antagonist approved for the treatment of overactive bladder (OAB) in adults and neurogenic detrusor overactivity (NDO) in pediatric patients. This work aimed to characterize the population pharmacokinetics of 5-hydroxymethyl tolterodine (5-HMT, the active metabolite of fesoterodine) and its pharmacokinetic/pharmacodynamic relationship in pediatric patients with OAB or NDO following administration of fesoterodine. Methods 5-HMT plasma concentrations from 142 participants of age ≥ 6 years were analyzed, and a nonlinear mixed-effects model was developed. Weight-based simulations of 5-HMT exposure and maximum cystometric capacity (MCC) were conducted using the final models. Results A one-compartment model with first-order absorption and a lag time, which included the effects of body weight, sex, cytochrome (CYP) 2D6 metabolizer status and fesoterodine formulation on pharmacokinetic parameters, best described the 5-HMT pharmacokinetics. An Emax model described the exposure–response relationship adequately. The median maximum concentration at steady state for pediatric patients weighing 25–35 kg and receiving 8 mg once daily (QD) was estimated to be 2.45 times greater than that in adults receiving 8 mg QD. Furthermore, simulation results showed dosing with fesoterodine 4 mg QD to pediatric patients weighing 25–35 kg and 8 mg QD to pediatric patients weighing >35 kg would achieve adequate exposure to demonstrate a clinically meaningful change from baseline (CFB) MCC. Conclusions Population models were developed for 5-HMT and MCC in pediatric patients. Weight-based simulations indicated that 4 mg QD for pediatric patients weighing 25–35 kg and 8 mg QD for those weighing > 35 kg provided similar exposures to those in adults following 8 mg QD and a clinically meaningful CFB MCC. Clinical Trial Numbers NCT00857896, NCT01557244
- 28 November 2022
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 19 (2) , 175.e1-175.e10
Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study
- 28 November 2022
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 19 (2) , 175.e1-175.e10
Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study
- 10 May 2020
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 107 (6) , 1273-1277
Oral Anticoagulants and Precision Medicine: Something Old, Something New
- 10 May 2020
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 107 (6) , 1273-1277
Oral Anticoagulants and Precision Medicine: Something Old, Something New
- 21 November 2019
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 107 (1) , 72-75
The Patient‐Centered Future of Clinical Pharmacology
- 21 November 2019
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 107 (1) , 72-75
The Patient‐Centered Future of Clinical Pharmacology